PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The overall design of the study is to perform both a PET and MRI scan on objectively
identified borderline personality disorder patients, to treat them with olanzapine for 8
weeks, and to then re-scan the patients with PET.
Phase:
N/A
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute